Your browser doesn't support javascript.
loading
Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.
Chatzis, Dimitrios G; Kolokathis, Konstantinos; Magounaki, Kalliopi; Chatzidakis, Stefanos; Avramidis, Konstantinos; Leopoulou, Marianna; Angelopoulos, Theodoros P; Doupis, John.
Afiliação
  • Chatzis DG; European University of Cyprus Medical School, Nicosia, Cyprus.
  • Kolokathis K; Department of Internal Medicine and Diabetes, Salamis Naval and Veterans Hospital, Salamis Naval Base, Salamis, Attiki, Greece.
  • Magounaki K; European University of Cyprus Medical School, Nicosia, Cyprus.
  • Chatzidakis S; European University of Cyprus Medical School, Nicosia, Cyprus.
  • Avramidis K; Department of Internal Medicine and Diabetes, Salamis Naval and Veterans Hospital, Salamis Naval Base, Salamis, Attiki, Greece.
  • Leopoulou M; Department of Cardiology, "Elpis" General Hospital, Athens, Greece.
  • Angelopoulos TP; Iatriko Paleou Falirou Medical Center, Athens, Greece.
  • Doupis J; Department of Internal Medicine and Diabetes, Salamis Naval and Veterans Hospital, Salamis Naval Base, Salamis, Attiki, Greece.
touchREV Endocrinol ; 17(2): 92-101, 2021 Nov.
Article em En | MEDLINE | ID: mdl-35118454
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a chronic disease with a constantly increasing prevalence worldwide. It is well established that T2DM affects both the macro- and microvasculature, and its presence is associated with a high risk of acute and chronic cardiovascular events. Traditionally, the management of T2DM has been mainly focused on the optimization of blood glucose levels with the use of antidiabetic medications. During recent years, however, an impressive accumulation of evidence has arisen from studies designed to explore the plausible effects of new antidiabetic drugs on cardiovascular outcomes in patients with diabetes. This review article aims to emphasize the findings of these studies and to highlight the substantial role of the newer classes of antidiabetic drugs in treating T2DM in a holistic, cardiorenal-metabolic approach, thus shifting the paradigm from the traditional, simplistic, glucose-lowering approach.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: TouchREV Endocrinol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Chipre

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: TouchREV Endocrinol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Chipre